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Abstract
Trypanosoma cruzi is an intracellular protozoan parasite and the etiological agent for Chagas
disease. Chagas is endemic in Latin America affecting 18-20 million people. However, currently
worldwide increasing numbers of the disease are being seen due to migration and globalization. This
neglected disease causes significant morbidity, mortality, and an economic burden. There are no known
vaccines and the only currently available drug is Benznidazole, but its effects are controversial.
Nonetheless, a therapeutic or prophylactic vaccine is of urgent need to alleviate this disease. In this
study we present an experimental approach using a synthetic peptide-based vaccine against T. cruzi.
The vaccine was developed based on a mucin-associated surface protein (MASP) (conjugated with
keyhole limpet hemocyanin (KLH) [MASPsyn]. The study was done using 6-8 week female
C3H/HeNHsd mice. 5 groups of mice were used: a placebo group was administered phosphate buffered
saline (PBS), adjuvant controls were additionally used, in which, one group was given 0.9% aluminum
hydroxide (AlOH), and another KLH. The experimental groups were separated into two groups: one
with the MASPsyn, and the other with the MASPsyn and 0.9% AlOH. The parasitemia and survival of the
mice were followed. After challenged with 1x105 trypomastigote Y strain, mice immunized with the
MASPsyn showed 80% survival followed for 1 year. qPCR showed low parasite burden in heart, liver,
and spleen (500-69 times less parasites than the placebo group before being euthanized 20-30 days post
infection). The humoral response was analyzed and detection of specific anti-trypomastigote lytic
antibody was detected in vaccinated mice, IgG1, IgA and IgM isotypes showed to be important in
eliminating the parasite. Moreover, cytokine measurements for IL-4, IL-10, IL-12, IL-17A, and IFN-γ
(relevant for resistance against the parasite) also showed to be increased in vaccinated mice. The
vaccine also seems to stimulate activation of both CD4+ and CD8+ T cells. Lastly, depletion of either
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CD4+ or CD8+ showed that CD8+ T cells are essential for protection. This neoteric vaccine is able to
control survivability by being able to prime both a humoral and cellular immunity.
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Chapter 1: Introduction
1.1

Chagas Disease
Trypanosoma cruzi is a flagellate protozoan that is the causative agent of Chagas’ disease.

Chagas’ disease affects 18-20 million people worldwide and has become a larger concern with
growing numbers of immigration. It is more commonly seen in South America, mainly because of the
high number of poor communities and the ideal living poor-conditions for the triatomine insect vector
[1].

Chagas disease has recently been emerging globally because of the increasing number of

immigration [2],[3]. In the USA there is reported to be 300,000 cases and it is speculated to be up to 1
million cases [4].
This parasite is a complex zoonosis as most mammals can serve as hosts and reservoirs for T.
cruzi infection and, therefore, can help in the distribution of the parasites through migration. Humans
are naturally infected with T. cruzi with the initial bite of an infected triatomine insect, also known as
a “kissing bug”. The insect is the vector for the parasite in which it delivers the infected form,
metacyclic trypomastigotes, through its feces [5]. The metacyclic trypomastigotes invade the host
cells and transform into amastigotes. In the cell, the amastigotes proliferate via binary fission and
eventually differentiate into trypomastigotes [6]. In this stage they are free in the blood and target
other cells for invasion and continue the infective cycle.

Once released into the blood the

trypomastigotes can be transmitted back into the kissing bug through a blood meal in which the
parasite transforms into an epimastigote in the insect’s gut [6]. The epimastigotes travel to the hindgut of the insect, and eventually differentiate into infective metacyclic trypomastigotes and the cycle
continues (Figure 1.1). The transmission of the parasite is usually from the vector (80%-90%), but it
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has known to be transmitted through other methods [7]. Such as contaminated blood (5-20%), organ
transplant, and congenital transmission (0.5-8%) [7].

Figure 1.1 Life cycle of T. cruzi.

After being infected with T. cruzi usually a chagoma forms at site of infection. This can
appear anywhere in the body as a form of edema that consist of inflammation due to rupture of
parasitized cells [7]. This is a result of the initial acute inflammatory response reaction. Symptoms
begin to appear 4 days to 2 weeks after infection [8]. These include spread of edema, chagomas
appearing in different parts of the body, but mostly the face. A unique edema to Chagas’, forms in
the upper and lower eyelid known as Romaña sign. Patients shortly (1-2 months) develop an acute
infection [7]. In which symptoms can arise as malaise, chills, high fever, muscles aches, and increase
exhaustion [8]. Acute infections are usually asymptomatic and self-limited [4]. The spleen can also
become palpable and the liver somewhat enlarged [8]. A non-painful rash can appear in the chest and
2

stomach area two weeks after infection [8]. Mortality rate is seen mostly in children with a 2-8% of
occurrence [7]. 60-70% of patients that survive live an intermediate status that does not develop into
the chronic phase of the disease [2]. 30-40% of Chagasic patients go on to develop chronic disease, of
which 0-50% are then asymptomatic [2, 7]. Other patients can have sporadic fever and appearances
of trypanosomes in the blood. Even though there is a small number of parasites still present in the
host during this stage there is an increase amount inflammation in affected tissues [5] [9]. In most
cases, symptomatic infection leads to congestive cardiac failure. Patients with Chagas’ disease have
a higher rate of having a stroke or arrhythmias [10]. During chronic stage parasites usually persist in
cardiac and smooth muscle causing inflammation, causing heart and digestive damage [11]. Other
results of chronic exposure of T. cruzi are megaesophagus and megacolon.
Approximately 22% of patients never seek healthcare and/or have limited access to proper
health care [12]. To add to the problem the drug treatment that has been developed is inadequate and
no vaccine is available. The only therapeutic agents that have been developed are nifurtimox and
benznidazole. However, nifurtimox is no longer available as a therapy due to its high toxicity level
[7]. Benznidazole, the only available drug, is extremely toxic, less effective in the chronic stage
(especially the late chronic stage), and a growing number of resistant strains are arising [13].

1.2

Host-Parasite interaction
T. cruzi survives in the human hosts mostly as in an intracellular parasite, consequently it is

critical to understand the host –parasite interaction. The parasite infects mostly all nucleated cells.
Taking advantage of the host’s vacuole, dividing in the protected cytoplasm, manipulating the
structure and pathways of the host’s cell [14]. There are two pathways that the parasite can invade
the cell, the lysosome dependent and independent. Either pathway requires the interaction of mucins
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on the surface of the protein to interact with the host cell. However, adhesion is not essential for host
invasion [15]. The parasite interacts with the extracellular matrix to infect the host cell [15]. The
surface of the parasite is covered by trans-sialidases and mucin-type glycoproteins that might help in
the attachment of the parasite to the host cell by using glycosylphosphophatidylinositol (GPI) anchors
[16].

1.3

Mucin-associated surface proteins
About 50% of the T. cruzi genome has repeated sequences encoding for retrotransposons and

genes for families of surface molecules [17]. These families include trans-sialidases (TS), mucins,
surface glycoprotein gp63 proteases, and mucin-associated surface proteins (MASPs) [17]. Mucins
are part of the largest super gene family in T. cruzi. Since the trypomastigote stage is directly
exposed to the immune response it is essential that it have a variety of mucins on the surface. Once in
contact with the environment the thick coat of mucins rapidly become negatively charged [18]. This
negative charge is a result of the transfer of sialic acid from the host [18]. The trypomastigote stage
contains a series of O-glycans that contain α-galactosyl residues, which are the main target epitope
for antibody production in chagasic patients [19] [18]. All of these surface molecules are known to
play key roles in the survival of the parasite.
T. cruzi uses several of these surface proteins to invade host’s cells and for parasite protection.
In their role of protection they ensure the targeting and invasion of specific cells or tissues [19].
MASPs constitute a large amount of those proteins, in which ~15% of the parasite’s genome encodes
for it and other mucin-encoding genes [19]. In the genome project for T. cruzi were found to MASPs
encodes for about >1300 genes [17]. Furthermore, since this family does not have any genes
orthologous to other sequenced kinetoplastid, it makes it very specific to T. cruzi [20]. Proteomic
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analyses of MASP showed that they are highly expressed in trypomastigotes [17, 21]. Genes are
present and expressed in low levels in the epimastigote and amastigote stage [17, 21]. MASPs are
characterized by a highly conserved N- and C-terminal domains, and a variable and repetitive central
region [22]. These domains encode for a presumed signal and a GPI-anchor addition site [22].
Studies from the El-Sayed’s [22] group demonstrated that MASP is GPI-anchored and shed into
medium culture, contributing to the believe that MASP play an essential role in the immune system as
well as the invasion of the host cell. MASPs are believed to have post-translational modifications
that contribute to the lack of the proteins interaction with other cells [23]. A conserved region in the
family of MASP was used to analyze the expression of MASP at different points of invasion, it was
found that there was an increase of expression in trypomastigote and amastigote forms of PAN4 and
CL-Brener strains [20]. This supported the already establish notion that MASP is upregulated in the
infectious stages [21, 23]. Due to previous confirmed studies that show that mammalian mucins
participation in cell-cell interactions, it is contemplated that MASPs could interact in the same way
[19]. This leads to the speculation that MASP is might be important for host cell invasion since the
other stages do not seem to require it for survival. Also, MASP52, obviously part of the MASP
family, was shown to play a role in the process of host invasion, as well as being secreted by
metacyclic trypomastigotes [20]. Bartholomeu et al (2009) reported that antibodies against a
conserved motif of MASPs reacted to the supernatant of parasites, leading to the belief that MASP
family members are shed into the culture medium [21]. Hence, it is worth to mention that MASP is
important for host cell invasion. Interestingly, according to Murta et al, MASP is up regulated in
resistant strains of T. cruzi compared to those susceptible to benznidazole. MASP expression is
known to be up-regulated in the mammalian stages [23].
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Trypomastigotes forms of T. cruzi secreted vesicles (TcVes), which showed to increase the
infection of macrophages (REF). Studies performed by Tricolli et al (2009) showed that mice pretreated with TcVes presented higher parasitemia and amastigote nests, as well as severe heart
pathology [24]. Proteomic characterization of TcVes showed MASP as one of molecules present in it.
Furthermore, from the 1,400 MASP encode in T. cruzi genome only one was present in TcVes, which
we called MASPves (Nakayasu, unpublished). This study will focus in the characterization of MASPves
as antigen for vaccination against Chagas disease.

1.4

Immune Response to Infection
The host immune system plays a great role in the infectivity of the parasite. Host resistance is

dependent on both the innate and adaptive immune response in a T. cruzi infection. Upon initial
infection the innate system is able to control parasitism with the involvement of cytokines and
activation of macrophages and natural killer cells (NK) [24]. Toll-like receptor (TLR) 2 is activated
by the parasite and promotes early-inflammation by dendritic cells [25, 26]. TLR-4 and TLR-9 have
also shown to contribute in the activation of host innate immune response leading to the regulation of
the infection [27]. The adaptive immune system in response to T. cruzi is fairly well understood. It is
known that Th1 CD4+ cells and CD8+ T cells recognize specific antigens from the parasite [28]. Later
on, parasitemia is usually controlled by several immune mechanisms such as macrophages,
opsonization by antibody, and T cell- mediated cytotoxicity [24]. Since the parasite has an
intracellular and extracellular phase the role of CD8+ and CD4+ T cells is crucial in the moderation of
the parasitemia. Abrogation of CD8+ and CD4+ T cells during the acute phase in model T. cruzi
infected mice, moderates myocardial inflammation [29], but showed high parasitemia and increase
mortality [29, 30]. Both in the acute and chronic phase, cardiac lesions have been characterized by
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having predominance for CD8+ T cells, fewer CD4+ T cells, and basically no B cells [29]. It has been
hypothesized that the adaptive immune response occurs after the first round of replication and
reinvasion (4-5 days post-infection) [28]. At this time, T. cruzi releases proteins that are processed by
MHC I [31], and are allowed for detecting from specific-parasite CD8+ T cells [28]. CD8+ T cells
were first analyzed with the identification of different epitopes in the TS gene family [32], surface
molecules such as MASP. This analysis showed that 30% of CD8+ T cell population in infection is
attributed to one TS epitope [32]. In addition, CD8+ T cells usually remain high and functional in the
chronic stage of the disease [28]. As has been mentioned when infection begins several T. cruzi
surface proteins are shed into the environment, this is an important role that should stimulate CD4+ T
cells [22].

CD4+ T cells are mainly responsible for controlling parasite replication [33]. Some

mucins are able to produce such an effect; however it is important to note that there is a superfamily
of surface proteins, SA85-1, that has been shown to possibly inhibit a CD4+ response [22].

1.5 Vaccines
The ideal vaccine for Chagas disease would be one that could be used for prophylactic and
therapeutic use because of the high number of people that are infected and/or at risk. Experimental
vaccines have been produced, but have failed to provide full protection when challenged with
parasites [1].

Some potential vaccine candidates have been explored and have shown partial

efficiency in protective immunity.

Those that have been studied are trypomastigote cDNA

expression library [34], paraflagellar rod proteins (PFR) [35], other parasite derived antigens such
amastigote surface protein (ASP)-2, ASP-1 [36], Tc52 [37], TolA-like surface protein [38], as well as
a variety of TS [39, 40] some of which have shave been experimentally used as vaccines and both fail
to provide a full protection. Mucosal vaccines have also been explored, among are those containing
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proteins such as recombinant cruzipain [41] and gp82 [42]. Besides the fact that these vaccines have
not provided full protection these studies have opened a window to understanding the vaccine that
needs to be created. The best targets would be genes that are expressed in the trypomastigote stage
since this is the stage that is exposed to the host’s cells most often [34]. Also, molecules such as TS
that are on the surface of the parasite are excellent targets since they are also exposed to the host’s
cell [39]. Previous studies have demonstrated that only one member of MASP family (MASPves), is
released in vesicles into the culture media by trypomastigotes (Nakayasu and Almeida, personal
communication). Based on this data we speculate that MASPves possibly will aid in the parasite
invasion of host cells.
Furthermore, since MASPves is released in vesicles it is also exposed to the immune system,
which is why we decided to explore the possibility to use this molecule as an antigen vaccine
candidate. Vaccination has been demonstrated to be a cost-effective approach to illness and death
caused by infectious diseases. Here we propose to study an individual MASPves as a vaccine
candidate.

Nakayasu et al (2012), using cell derived trypomastigotes performed a proteomics-

immunoinformatics analysis finding high number MASPs and other surface proteins to have high
binding of MHC I and/or II molecules, which make them very valuable as targets for development of
vaccines [43]. In further investigation also through proteomic analysis it was shown that a specific
MASP is found in vesicles (MASPves) secreted by trypomastigotes. In addition, our computational
analysis of MASPves indicated the presence of several B-cell, MHC class I and II T-cell epitopes in
this molecule in both human and murine. This is a good target since MASPves epitopes can in
principle fit into most known human and murine MHC class I and II alleles, thus suggesting that
specific B-cell and T-cell responses toward infected cells and parasites could be triggered.
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1.6

Hypothesis
The ideal vaccine against the complex intracellular and extracellular T. cruzi is one that can

elicit both a humoral (antibody production) and cellular immune response. In this study, we tested the
ability of a synthetic peptide-based (conjugated with KLH) vaccine (MASPsyn) to provide protection
against T. cruzi. Based on in silico analysis, we hypothesized that: our peptide (MASPsyn) will be able
to stimulate effectively the humoral and cellular immune response providing protection against
Chagas disease in the murine model. Furthermore, the epitopes contained in the vaccine candidate
will show similar effect among human infection protection, since theoretically this peptide would be
recognized by several MHC I and II haplotypes.

1.7 Specific Aims:
Specific aim 1: To evaluate the humoral response to MASPsyn.
Specific aim 2: To validate MASPsyn as vaccine candidate.
Specific aim 3: To determine the Th response induced by MASPsyn.
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Chapter 2: Materials and Methods
2.1 In vitro epimastigote culture
T. cruzi Y strain epimastigote were cultivated 4 days at 28°C in Liver-infusion tryptone (LIT)
supplemented with 10% inactivated fetal bovine serum (Sigma, St. Louis, MO) [44].

2.2 In vitro and in vivo trypomastigote culture
T. cruzi Y and Talahuen strain trypomastigotes were kept in culture by alternating infecting
BALB/c mice and monkey kidney epithelial cells (LLC-MK2, American Type Culture CollectionATCC, Manassas, VA).

After five passages, BALB/c mice were infected with 1x 104

trypomastigotes. After 3 days bloodstream trypomastigotes were obtained and were used to infect
LLC-MK2. Cells were kept at 37°C in a humid atmosphere supplemented with 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% inactivated fetal bovine serum and 5%
Antibiotics (ampicillin/ streptomycin) (Sigma, St. Louis, MO) [44].

2.3 Cloning of MASPves
The complete open reading frame of the mature T. cruzi MASPves (excluding the sequences
encoding for the signal peptides for secretion and GPI insertion) was amplified using oligonucleotides
S1- Xho I sense (5’-GGGATCCGAGCTCGAGG GGGATGATGATGTTTCTGGT) and S2- Hind III
antisense (5’ CAGCCGGATCAAGCT TAGTGTCGCCGGTGGTTGTTTT). Polymerase chain
reaction (PCR) was performed using PCR master mix (Promega, Madison, Wisconsin) and 100 ng T.
cruzi Y strain total genomic DNA [45]. The PCR product was ran in a 0.8% agarose gel and purified
using Wizard SV Gel and PCR clean-Up system (Promega, Madison, WI). The amplified fragments
were cloned into the pGEM-T vector system I (Promega, Madison, WI) and used to transform
10

Escherichia coli DH5α. The clone MASPves/pGEM was sequenced (Genewiz, Inc, South Plainfield,
NJ) and was confirmed using Basic Local Alignment Search Tool (BLAST) and Multiple Sequence
Alignment by CLUSTALW (http://align.genome.jp/). MASPves/pGEM was digested using the
restriction enzymes Xho I and Hind III, and then MASP was directionally subcloned into the
expression vector pRSET A (Invitrogen, Carlsbad, CA). The MASPves/pRSET clones were selected
by colony screen and the positive clone ORF was confirmed by sequencing (Genewiz, Inc, South
Plainfield, NJ). E. coli BL21 (DE3) (Invitrogen, Carlsbad, CA) was transformed with
MASPves/pRSET A for expression.

2.4 Expression and Purification of MASPves
The expression of MASPves cloned in pRSET A was induced using isopropyl β-D- 1thiogalactopyranoside (IPTG) at a final concentration of 1 mM. The expression was induced for four
hours. To determine the optimum induction time, aliquots of 1 mL were collected immediately before
and each hour after induction. 20 µL of non-induced and induced samples were resolved in 12%
SDS-PAGE. The recombinant MASPves was purified using B-PER 6XHis Fusion Protein Spin
Purification Kit (Thermo Scientific, Rockford, IL).

2.5 Western Blot Analysis of recombinant MASPves
15-μl from each elution of the protein purification was electrophoresed on a 12% SDS-PAGE
and blotted onto Nitrocellulose membrane (Thermo Scientific, Rockford, Illinois) as described by
[46]. Membrane was first was blocked (5% skim milk PBS for 1 hr or overnight), follow by
incubation with anti-6XHis (1:5000) antibody (Invitrogen, Carlsbad, CA), washed 3 times with PBSTween, and then incubated with anti- mouse antibody IgG (H+L) HRP conjugated antibody
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(1:10000) (Invitrogen, Carlsbad, CA). Blots were developed by chemiluminescence following the
manufacturer’s instructions (ECL kit, Thermo Scientific, Rockford, IL).

2.6 HPLC
To purify MASPves, to homogeneity, it was subjected to High Performance Liquid
Chromatography (HPLC).

Solid phase extraction was done of the samples to remove salts before

loading them into the HPLC. The DSC-18 (Discovery, Bellefonte, PA) were activated with 100%
methanol, then equilibrated with 0.05% trifluoroacetic acid (TFA), after which the sample was
loaded, the sample was then washed with 0.05% TFA, and finally eluted (80% Acetonitrile (ACN),
0.05% TFA). The sample was dried using a SpeedVac, then the pellet was resuspended in 0.05%
TFA, and centrifuged for 5 minutes at 14,000rpm 4°C. Sample was then loaded onto a Jupiter 5μ C18
300A HPLC column and eluted with a gradient of increasing ACN concentration.

2.7 Protein Purification from Gel extraction
After affinity chromatography purification the recombinant MASPves was submitted to other
step of purification by gel extraction. The MASPves eluted fractions were resolved in a 12% SDSPAGE. The gel was placed in freezing KCl (250mM) and shacked at 4°C. The protein was cut out
from the gel and placed in 50 mL conical tubes with 10 mL of distilled water with protease inhibitors.
The tubes were placed under constant agitation at room temperature for 24 hours. To remove excess
SDS the samples were subdued to dialysis against 4 L of PBS at 4°C for 48 hours. The samples were
quantified and a western blot was done to detect the protein.
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2.8 Selection and synthesis of the synthetic MASP ves peptide (MASPsyn)
Using adequate computational analyses (ABCpred prediction server for B cell epitope
recognition, ProPred I, SYPEITHI, and HLA-BP for MHC I, and TEPITOPE and ProPred for MHC
II recognition) we chose a peptide from the protein that seemed to have a high score of epitope
recognition in B-cell recognition, MHC I and MHC II in humans and mice. Synthetic MASPves
peptide was synthesized by the company thinkpeptides (thinkpeptides, Bradenton, FL). The peptide
was conjugated to KLH.

2.9 Custom Antibody Selection
Two epitopes were selected from MASPves because of their high immunogenicity. One was used for
the production of the synthetic peptide MASPsyn and the other was employed to develop a custom
antibody (MASPcus). MASPcus was prepared in rabbits on request by Biomatik Research Inc.
(Biomatik Research Inc., Wilmington, DE).

2.10 Immunization
C3H/HeNsd (Harlan Laboratory, Indianapolis, IN) female mice (6-8 weeks old) were
separated in five groups (4 mice/group). The immunizations were performed via intraperitoneal (i.p.).
One control group was immunized with phosphate buffer saline (PBS, placebo). Two control groups
for the adjuvants, [0.9% AlOH] (Sigma-Aldrich, St. Louis, MO); and KLH [10 μg/mouse] (SigmaAldrich, St. Louis, MO); and two experimental groups. To the experimental groups were
administered 20 μg/mouse of MASPsyn alone and combined with 0.9% aluminum hydroxide,
respectively. A total of 3 immunizations every 10-15 days were administered.
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The rational to use AlOH as adjuvants are: 1) it has been the only approved adjuvant allowed
to use in human vaccines by the US federal drug administration (FDA) [47]. 2) It is known to
stimulate CD4+ T cells, secretion of cytokines, act on macrophages and monocytes, and enhance
expression of MHC I [48, 49]. 3) It is also known to stimulate a Th1 –type immune response [50],
which has also been shown to help regulate the infection [40, 51].
The procedures described in this study were performed minimizing the distress and pain for
the animals following the NIH and ARRIVE guidelines, the animal protocol was approved by The
University of Texas at El Paso (Protocol Number: A-2125) Institutional Animal Care and Use
Committee (IACUC).

2.11 Vesicle purification
Trypomastigotes were collected at different days of culture (first and second day post-infection)
and diluted to 1x108 parasites/ml with DMEM 12.5 g/L glucose. Trypomastigotes were incubated for
4-6 hours (no longer than 8 hours) at 37°C and 5% CO2.

After, the parasites were centrifuged at

3,000 x g for 7 minutes at 4°C and the supernatant was collected and filtered using 0.45 μM filters
(Thermo Scientific, Rockford, IL). The filtrate was collected and centrifuged at 100,000 x g at 4°C
for 2 hours. The pellet (S1) was resuspended in 500 μL of PBS and with 1:10 protease inhibitor
cocktail (Sigma, St. Louis, MO) was added. The supernatant was collected and centrifuged 100,000
x g at 4°C for 16 hours. After, a second pellet (S2) was resuspended in 500 μL of PBS with 1:10
protease inhibitor cocktail. The vesicle suspension was stored at 4°C until use.
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2.12 Isolation of amastigotes
LLC-MK2 cells were infected with 1 x 108 trypomastigotes. After 5 days, the infected
monolayers were gently detached by scraping and resuspended in 5 mL of PBS. The suspension
containing the infected cells was next transfer to an M-tube (Biotec, CA). This tube has a special
stator and rotor that allows for tissue homogenization. It has a pre-inserted mesh that retains larger
particles, removing them from the homogenized sample. The tube was then placed in the
gentleMACS™ Dissociator (Biotec, CA) for the automated disruption of host cells.

The

homogenized sample containing the parasites was then passed through a column containing anion
exchange preswollen microgranular diethylaminoethyl cellulose (GE Healthcare, NJ). The sialylated
trypomastigote forms of the parasites were retained in the resin, while the amastigote forms were
recovered [52].

2.13 Lysis of parasites and vesicles
Parasites were cooled on ice for 5 minutes, then centrifuged at 3,500 rpm at 4°C for 10
minutes. The supernatant was removed and the pellet was washed 3 times with PBS (each time
centrifuged for 10 minutes at 3,500 rpm). After the washes, 300 μL of lysis buffer (50 mM sodium
fluoride, 1 mM sodium ortho-vanadate, 1% triton, 10 mM TRIS, 5mM EDTA, 50 mM sodium
chloride, and 30 mM sopdium purophospahte) was added to the pellet. The samples were then
nutated for 10 minutes at 4°C, followed by centrifugation at 14,500 rpm for 10 minutes at 4°C. The
pellet was kept for immunoprecipitation or directly added to the SDS-PAGE gel. The vesicles were
lysed following the above procedure.
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2.14 Immunoprecipitation of MASPves from trypomastigotes
Two microliters of anti- MASPsyn was added to the lysed pellets (parasites) and left incubating
at 4°C overnight. The next day, 40 μL of protein G-sepharose (Thermo Scientific, Rockford, IL) was
added and incubated for 1 hour at 4°C. Subsequent, the samples were centrifuged for 1 minute at
10,000 rpm and washed 3 times with 750 μL of lysis buffer. Aliquot of the samples were then
analyzed in SDS-PAGE gel.

2.15 Immunoblotting
IP from epimastigote, amastigote, trypomastigote (Y and Talahuen strain), and vesicles (15
µL of each) were subjected to electrophoresed 12% SDS-PAGE and blotted onto Nitrocellulose
membrane (Thermo Scientific, Rockford, IL) as described by [48]. Membrane was first was blocked
(5% skim milk PBS overnight), followed by incubation with anti-MASPsyn (1:5,000) antibody
(obtained from immunized mice, see section 2.10), washed 3 times with PBS-Tween, and then
incubated with anti- mouse antibody IgG (H+L) HRP conjugated antibody (2:10,000) (Invitrogen,
Carlsbad, CA). Blots were developed by chemiluminescence following the manufacturer’s
instructions (ECL kit, Thermo Scientific, Rockford, IL). The lysed vesicles were analyzed similarly,
as described above.

2.16 Evaluation of humoral immune response
Ten days after the last immunization blood was collected by tail bleeding [53] and serum was
separated from blood by centrifugation at 2,000 rpm for 10 min. The serum antibody titers were
determined by an ELISA [54]. Human Chagasic and normal serum (kindly donated by Dr. Almeida UTEP) were also tested for antibody titers against MASPsyn.
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2.17 Immunoglobulin Isotyping
Immunoglobulin isotyping was examined using Mouse Immunoglobulin Isotyping ELISA Kit
(BD Pharmigen, San Jose, CA). The serum from the placebo and MASPsyn immunized groups was
obtained as described above. The positive control was provided in the kit. The assay was performed
following the manufacture guidelines; each sample was done in triplicates and read at an absorbance
of 450 nm using VERSAmax microplate reader (Molecular Devices, Sunnyvale, CA).

2.18 Challenge - Parasitemia and Survival
Ten days after last immunization mice were inoculated via i.p. with 1 x 106 trypomastigote Y
strain, the parasitemia and survival were monitored. The parasitemia was evaluated every day for the
first 12 days then every third day for a total of 21 days following the Brenner method [55].

2.19 Evaluation of cytokines
Four weeks post-infection the blood was collected by tail-bleeding [55] and pool of serum
from each experimental group was obtained as described above. Cytokines were measured using
Mouse Inflammatory Cytokines Multi-analyte ELISArray Kit (Qiagen, Valencia, CA).

2.20 Detection of CD4+ and CD8+ in immunized and acutely infected mice using Flow Cytometry
Eight days post-infection the mice were sacrificed (non-infected and infected). The spleens
were harvested and ground through a 0.4 μM nylon mesh. Cell suspensions were filtered through a
second nylon mesh. Afterwards they were centrifuged at 1,200 rpm for 5 minutes to pellet cells.
Cells were resuspended in lysis buffer. Cells were centrifuged again at 1,200 rpm for 5 min. To
avoid unspecific binding cells were blocked with mouse serum for 15 minutes in 4°C. Cells were
17

double stained with anti-CD4-FITC, and anti-CD25-biotin or anti-CD69- biotin, the same procedure
was performed with nti-CD8-PE. A secondary streptavidin-PC5 antibody was added to antiCD25/69-biotin stained cells. Cells were left to stain for 1 hour at 4°C wrapped in foil. The cells
were then washed with FACS buffer (PBS, 1% fetal calf serum, 0.1% Sodium Azide, and 0.5 mM
EDTA) and centrifuged for 5 min at 1200 rpm. The supernatant was tossed and the cells were then
resuspended with 300 μL of 1% paraformaldehyde (PFA). Aliquots from cell suspension were taken
for individual control stains to verify the presence of CD4+ and CD8+ cells by staining individually for
anti-CD4-FITC, anti-CD8-PE, anti-CD25-biotin and anti-CD69-biotin and subjected to the same
treatment as samples. Samples were then analyzed with flow cytometry using Cytomic FC 500 flow
cytometer (Beckman Coulter, Miami, FL). For each individual sample, approximately 10,000 events
were acquired and analyzed using CXP software (Beckman Coulter, Miami, FL).

2.21 Detection of CD4+ and CD8+ in mice with chronic stage infection using Flow Cytometry
Immunized mice were chronically infected with 1x104 trypomastigotes. The experimental
groups were negative control (PBS), AlOH, MASP and MASP/AlOH. In parallel the same group
were not infect to be used as control for naïve CD4+ and CD8+ mice. The survived animals were
euthanized nine months after challenge. A boost immunization was given seven days before the
animals were sacrificed. The spleens were collected and processed as described above for detection of
CD4+ and CD8+.
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2.22 In vivo depletion of immune cell subsets
One week after the last immunization, mice received i.p. injections of 500 μg anti-CD4 (BD
Pharmigen, San Jose, CA) or 1000 μg of anti-CD8 (BD Pharmigen, San Jose, CA) mAbs. Unspecific
IgG was given to the control groups. Depletion was analyzed by flow and the data were acquired
using Cytomic FC 500 flow cytometer (Beckman Coulter, Miami,FL). For each individual sample,
approximately 10,000 events were acquired and analyzed using CXP software (Beckman Coulter,
Miami, FL). Mice were then challenged with 1 x105 trypomastigotes 48 hours after last dose of antiCD4/CD8. Parasitemia and survival were followed as described.

2.23 DNA preparation
In the terminal stage of the disease mice were euthanized and the heart, liver and spleen
tissues were collected. This procedure was performed at different end points upon the protection
offered by the immunization. DNA was extracted using Wizard SV Genomic DNA Purification
System (Promega, Madison, WI) and quantified by Nanodrop 1000 Spectrophotometer (Thermo
Scientific, Waltham, MA).

2.24 Real-time PCR
Each PCR reaction contained 50 ng genomic DNA, 0.5 μM of T. cruzi 195-bp repeat DNAspecific primers TCZ-F 5’GCTCTTGCCCACAMGGGTGC-3’ where M=A or C and TCZ-R 5’CCAAGCAGCGGATAGTTCAGG-3’ primers were obtained from Integrated DNA Technologies
(IDT) (Integrated DNA Technologies, Coralview, IA) [56]. In addition, 12.5 μL of IQ SYBR Green
Supermix (Bio-Rad, Hercules, CA) and RT-PCR-grade water (Life Technologies, Grand Island, NY)
was added to a final volume of 25 μL. Independently, reactions containing 50 ng genomic DNA, 0.5
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μM of murine-specific tumor necrosis factor-α (TNFα) primers TNF-5241 5’ TCCCTCTCATCAGTTCTATGGCCCA-3’ and TNF 5411 5’-CAGCAAGCATCTATGCACTTAGAC- CCC-3’,
(Integrated DNA Technologies, Coralview, IA) [56], 12.5 μL of IQ SYBR Green Supermix and RTPCR-grade water were added to a final volume of 25 μL. Negative controls with no DNA added
were done. All reactions were performed in triplicate. The reactions were placed onto a 96-well plate
(Bio-Rad, Hercules, CA), centrifuged for 2 min at 2000 rpm, and placed in the Eppendorf
Mastercycler ep Realplex (Eppendorf, Hauppauge,NY). The reactions were exposed to four phases,
denaturation, amplification, melting, and cooling. The denaturation phase the plate is heated to 95°C
for 2 min, the amplification was done during 35 cycles for T. cruzi primers (45 cycles for TNFα
primers) at three steps: 95°C for 15 s, then 65°C for 10 s, 72°C for a 5 s hold, and then 79°C for 20 s,
at which the fluorescence intensity is acquired. The melt phase then begins with 95°C for 15 s, then
60°C for 15s, and finally 95°C for 15s hold. Data was collected and analyzed using the software
provided in the Eppendorf Mastercycler ep Realplex. Also, the amplification products for each
sample were subjected to ethidium bromide, ran through an electrophoresis 1% agarose gel, and
finally viewed under UV light.
The standard curve for the qPCR reactions were generated as described by Cummings and
Tarleton [56]. Briefly, to 150 mg of normal tissue was added 3 x 106 T. cruzi trypomastigotes, and
then the DNA was extracted (Wizard SV Genomic DNA Purification System, Promega, Madison,
WI). DNA was quantified using Nanodrop 1000 Spectrophotometer (Thermo Scientific, Waltham,
MA). The standard curve obtained was used to determine the parasite load of infected tissues.
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2.25 Trypomastigote Lysis Assay
Pool of serum was collected from non-infected placebo (complement system active), MASPsyn
immunized (complement system active), and MASPsyn immunized (inactivated complement system,
56°C for 30 min,) mice. Trypomastigote suspensions (200 μL of 1 x 107 parasites/mL, in DMEM)
were incubated with 0.8 μL (1:250) of either serum at 37°C for 1 hr. Then propidium iodine (PI) was
added (0.5 μg/mL) and cells were incubated for 5 min. at 24°C, followed three washes with PBS. The
pellet was re-suspended in 4% paraformaldehyde, incubated at 24°C for 15 minutes, and then washed
with PBS. Finally, the pellet was resuspended in 300 μL PBS. The positive and negative controls
(live and dead parasites, respectively) were prepared similarly. Briefly, the trypomastigote suspension
(200 μL of 1x107 parasites/mL in DMEM) was washed three times with PBS and PI was added (0.5
μg/mL), then followed by three washes with PBS, the parasites were then fixed with 4%
paraformaldehyde, followed by three PBS washes, and finally resuspended in 300 μL PBS. In the
negative control the trypomastigote suspension was treated with hydrogen peroxide (200 μM), then
washed with PBS, the pellet was resuspended in PI (0.5 μg/mL), then followed by three washes with
PBS, the parasites were then fixed with 4% paraformaldehyde, followed by three PBS washes, and
finally resuspended in 300 μL PBS. The samples were evaluated by flow cytometry using Cytomic
FC 500 flow cytometer (Beckman Coulter, Miami, FL). The experiment was performed in triplicate
in three independent experiments. For each individual sample, approximately 10,000 events were
acquired and analyzed using CXP software (Beckman Coulter, Miami, FL). The results were plotted
as a percentage of dead parasites.
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2.26 Statiscal analysis
Stastisitical significance of comparison of mean values was evaluated by a one-tailed
ANOVA Student’s t-test, two-way ANOVA using GraphPad Prism 5 software (GraphPad Software,
Inc. La Jolla, CA).
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Chapter 3: Results
3.1 Production of recombinant MASPves
The recombinant MASPves (42.62 kDa) was expressed in E. coli (BL21) and purified by affinity
chromatography, using B-PER 6XHis Fusion Protein Spin Purification Kit following the manufacture
protocol (Thermo Scientific, Rockford, IL). The MASPves was eluted using 200, 150, and 100 mM,
the purity of the protein was verified by SDS PAGE. The Figure 1A showed large contamination with
bacterial proteins when used 200 mM imidazole (Figure 1A). We believe that at the concentration of
150 mM imidazole the protein was the purest; nevertheless, other protein bands still were observed in
the gel.

Figure 3.1. SDS-PAGE of the
recombinant MASPves purified by
affinity chromatography. A) Elution
using 200mM imidazole buffer B)
Elution using 200 mM imidazole
elution buffer C) Elution using 150
mM imidazole elution buffer.

The western blot (Figure 3.2) effectively confirms that MASPves correspond to 42 kDa band in the
SDS-PGE (eluted at 150 mM imidazole). The recombinant protein was detected using anti-6XHis
antibodies.
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Figure 3.2. Western blot of MASPves purified by affinity chromatography. The recombinant protein
was eluted 4 times using 150 mM imidazole, the fractions collected were resolved in SDS-PAGE
12%, blotted and MASPves was identity was confirmed using anti-6XHis monoclonal antibodies by
western blot. P, whole cell extract. E1, elution 1. E2, elution 2. E3, elution 3. E4, elution 4.
Since the purification by affinity chromatography was not sufficient to obtain a pure protein, the
elution fractions of the purified proteins were further subjected to HPLC. Fractions were collected 1
mL/min for 80 minutes and MASPves seemed to have been eluted between the 5th through the 10th
minute where was observed a high peak (Figure 3.3)

Figure 3.3. HPLC elution profile of MASPves with increasing acetonitrile gradient and the resulting
A280 nm and A214 nm readings. Samples were collected from elution peak.
These fractions were then quantified, western blotted, and submitted for mass spectrometry.
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The results were not favorable since we were not able to detect the protein using any of the
techniques mentioned above. As a consequence, fractions from the first minute to the 15th were
subjected to these procedures as well. The protein was not detected in any of these fractions by
western blot or mass spectrometry.
Since the protein was not detected, a different approach was taken. The protein was purified
straight from the gel and the samples were subjected to dialysis. After, this procedure the protein was
not detected by western blot or by quantification. Therefore, we conclude that the recombinant
MASPves was degraded during the purification process and we decided to produce a synthetic peptide.

3.2 Selection and synthesis of the synthetic MASPves peptide (MASPsyn)
The selection of the peptide was based on computational analyses that showed the highest
number of potential peptide binding to both human and mice MHC I and II as well as its antigenicity
prediction.
The amino acid sequence of MASP contains two signal peptides, one at the N- and other at Cterminal. The N-terminal peptide is for a responsible for targeting MASPves to the endoplasmic
reticulum (ER), while the C-terminal is replaced by a GPI-anchor in a post-translation transamidation
reaction [57, 58]. The computational analysis for antigenicity, MHC I and II binding peptide were
performed with the mature MASPves.

Figure 3.4. Schematic representation
of computational analysis strategy.
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Table 3.1. MASPSYN MHC class-I Binding Peptide Prediction, threshold 5%. (ProPred prediction
server). Human alleles (1-15) and mice alleles (16-17). Blue letters represent binding site, red
letter represents the putative anchor amino acid. The score represents the probability of its
binding to given MHC molecule

Table 3.2. MHC II peptide binding prediction.
Blue letters represent binding site, red letter
represents the putative anchor amino acid.

Table 3.3. Summary of the immunological theoretical activity of MASPsyn . MHC I and MHC II
predicting binding sites and antigenicity. The ABCPred software predict a 70 % of chances that B cell
generate antibodies against this peptide.
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Synthetic Peptides alone are known to have low antigenicity, for this reason we decided to conjugate
MASPsyn to keyhole limpet hemocyanin (KLH). KLH works as peptide carrier and stimulator of the
immune system, through interaction with T cells, monocytes, macrophages, and polymorphonuclear
lymphocytes [59].

3.3 Immunoblotting
Using serum from mice immunized with MASPsyn a western blot analysis was done for
detection of MASPves at the different stages of the parasite.

Immunoprecipitation of the

trypomastigote stage two different strains, Y and Talahuen were analyzed. Epimastigote, amastigote,
and trypomastigote from Talahuen and Y strain all show to have the presence of MASPves (Figure
3.5A-B).
Furthermore, vesicles were collected at different time points, first and second day of shedding
material from trypomastigotes in culture. Vesicles were then fractionated to collect different sizes
(S1>100 nm, S2 <100 nm, and S3: Pellet after acetone precipitation). At the time of this experiment,
the pool of serum of α-MASPsyn from immunized mice was limited because of the continuous use of
the serum for other experiments and to preserve the wellbeing of the mice, consequently, we had a
custom antibody made (α-MASPcus). This antibody was produced with a different MASPves peptide
sequence than the synthetic. Using MASPcus we were able to detect vesicles from first day of
shedding material, and also in vesicles <100 nm from the second day of shedding. Vesicles from the
first day have also been recognized by α-galactosyl antibodies (Almeida, personal communication),
which are found at elevated levels in Chagasic patients [60].

On the other hand, this is the first

reported marker to detect vesicles at such later shedding (Figure 3.5C).
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Figure 3.5. Immunoprecipitation and western blot. Detection of MASPves by antibodies present in
sera from mice immunized with MASPsyn (A-B) . A) Immunoprecipitation of Trypomastigote form of
Talahuen and Y strain. B) Lysates of Epimastigote and amastigote stages. C) Vesicles from first and
second day shedding using α-MASPcus. Sizes of vesicles S1>100 nm, S2 <100 nm, and S3: Pellet
after acetone precipitation.
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3.4 Humoral immune response
It has been shown that parasite specific antibody production in T. cruzi infected mice aid in
the survival.[61]. The purpose of this experiment is to determine capability of MASPsyn peptide to
elicit a protective humoral immune response.
Pooled sera was collected from all immunized mice groups twelve days after last
immunization to determine total IgG antibody levels by ELISA, the dilution of the sera at 1:100
provided specific MASPsyn antigen specific antibodies. To determine the production of antibodies
against this epitope in the human infection Human Chagasic and non-Chagasic serum were used as
positive and negative control. As expected, mice immunized with MASPsyn and MASPsyn/AlOH both
showed antigen-specificity of antibody response as well as the human Chagasic serum (Figures 3.6A
and 3.6B), while the non-Chagasic serum did not showed any reactivity. MASPsyn/AlOH had a
slightly higher detection than the MASPsyn group (not significant).

Figure 3.6. Antibody levels from pooled whole serum of non-infected mice (all groups) 10 days after
last immunization and pooled human Chagasic serum. A.) Detection of anti- MASPsyn IgG levels
were done in triplicates per group and by ELISA. Higher levels of antibody titer were detected in
MASPsyn and MASPsyn/AlOH groups. B.) Serum from Chagasic human patients also showed an
increase level of antibody titer against MASPsyn when compared to normal human serum.
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3.5 Immunoglobulin Isotyping
Immunogloblin (Ig) isotyping was also of interest since the acute phase of the disease is
characterized for hypergammaglubulinemia, especially higher titers of IgA, IgM and IgG especially,
IgG1, IgG2A, IgG2B isotype antibodies (lytic antibodies) which are considered to have antiparasitic
properties [62-64]. In immunized-not infected mice, higher levels of IgA, IgM (p≤ 0.05), IgG1 (p≤
0.05), IgG2A were detected (Figure 3.7). The data states that MASPsyn as vaccine is stimulating most
suitable Igs to kill the parasite.

Figure 3.7. Effects of vaccine on production of different immunoglobulins (Ig). A.) Pool serum
(n=4/group) from non-infected immunized mice was analyzed by ELISA for Ig isotypes (IgG1,
IgG2A, IgG2B, IgG3, IgA, IgM). PBS serum was used as a baseline control, and the positive
controls were used from the kit to mark for presence of corresponding Ig. Experiment was done in
triplicates per Ig. P-value: p ≤ 0.05 = (*).
3.6 Lysis Assay
It has been characterized that Chagasic patients as well as experimental chronic infected mice
produces lytic antibodies (IgGs) are able to bind to the membrane surface of trypomastigotes aiding
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to control T. cruzi infection [65], by lowering the parasitemia. In this regard, the lysis assay was
performed to address the possible lytic activity of the anti-MASPsyn antibodies produced by immunize
mice. In this experiment live trypomastigotes were incubated with α- MASPsyn serum, with inactive
and active complement, to verify specific MASP-antibody and background lytic activity of the
immune system, respectively. Figure 3.8 shows that MASPsyn serum is able to lyse the
trypomastigotes 3.4 fold higher than the placebo serum (which was taken from mice immunized with
PBS and had active complement).

Figure 3.8. Trypomastigote lysis by MASPsyn antibody from whole serum immunized mice. A.)
Serum from not immunized, not infected mice was collected and was used freshly with natural active
complement for the experiment (MFS: Mice fresh serum). Fresh serum from immunized mice and
active complement (FMASPsyn). Complement system was deactivated in the serum collected from
non-infected immunized (MASPsyn group) mice (MASPsyn). Live trypomastigotes were used as
negative control (0% lysis) (C-). A positive control of dead trypomastigotes (≈ 75% lysis) was also
used (C+). The sera from immunized mice (inactivated complement) was able to lyse trypomastigotes
more effectively than the placebo group. The data is representative of 3 independent experiments. Pvalue: p ≤ 0.05 = (*).
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3.7 Parasitemia and Survival
The parasitemia in all groups was followed for 20 days post-infection. Mice immunized with
MASPsyn alone or with adjuvant did not show any significant decrease in parasitemia during the time
monitored (Figure 12A). Survivability was followed as well. Our data shows that immunized mice
with solely MASPsyn increased survival to 80% for up to a year, when the experiment was ended
(Figure 12B). In the case of immunized mice with AlOH and MASPsyn/AlOH low survival was
observed. In both groups all mice were dead at 15 and 22 days post-infection respectively. Also, in
Figure 12B it is shown that mice immunized KLH (control for KLH immunogenicity) are not able to
control infection and all die by day 23. This control group was used to address the possible role of
KLH (conjugated to the peptide) in the survived mice.
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Figure 3.9. Parasitemia (A) and survival (B) of mice infected with 1x106 Trypanosoma cruzi Y strain
trypomastigotes. A.) Parasitemia levels are shown as trypomastigotes/ml of the mice infected. Each
point corresponds to the mean parasitemia level in blood of mice groups. Blood parasitemia was
followed in all groups (n=4/group). From the 3rd to the 20th day post-infection, 5 μL of blood was
taken from the tail and the number of trypomastigotes was counted. B) Survival was monitored daily
in all groups (n=4). Each point is representative of one mouse. Three independent studies were done
with similar results.
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3.8 Real-time PCR
In order to test if the vaccine produces sterile protection to the immunized mice qPCR was
performed. The heart, liver and spleen were removed from all animals at the humane endpoint (see
Figure 3.9). DNA was extracted and a RT-PCR analysis, with proper controls, was done to determine
the parasite burden in the selected organs. MASPsyn and MASPsyn/AlOH groups both showed lower
amount of parasites in all organs. More exceptionally, mice that had been immunized with MASPsyn
and survived past a year had statistically significant lower burdens in all organs when compared to
PBS (placebo control) (Figure 10).

Figure 3.10. Parasite burden in heart, liver, and spleen of immunized mice infected with 1x106
Trypanosoma cruzi Y strain trypomastigotes. Each bar represents corresponding organs of one
mouse, done in triplicates. Data are a comparison of parasite (trypomastigote form) burden of 50 ng
of DNA isolated from infected corresponding organ.

Mice immunized with MASPsyn had

significantly lower parasite burden in all organs (heart: P value of p ≤ 0.001 (***), liver p ≤ 0.01 (**),
spleen p ≤ 0.001 (***).
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3.9 Evaluation of cytokines
Stimulation of cytokines play a crucial role in resistance of Chagas disease. Therefore, we
analyzed the cytokine profile of mice immunized with MASPsyn. Four weeks after the last
immunization, serum was collected and the cytokines measured were IL-1A, IL-1B, IL-2, IL-4, IL-6,
IL-10, IL-12, IL-17A, IFNγ, and TNFα (not all shown) via ELISA. Circulating cytokines that were
seen to have a significant increase in either MASPsyn or MASPsyn/AlOH groups when compared to the
PBS group were IL-4, IL-10, IFNγ, IL-12, and IL-17A (Figure 8A-E). Expectantly, the vaccine
induced cytokines that are known to play an important role in the response to a T. cruzi infection [6673].
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B.

Figure 3.11. Pool serum cytokine levels of non-infected, immunized mice 4 weeks post-last
immunization. Cytokines were assayed in triplicate by ELISA. A.) IL-4, Difference in PBS and
MASPsyn/AlOH is statistically significant with a P-value of p ≤ 0.05 (*). B.) IL-10, Difference in
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production level in PBS and MASP is statistically significant with a P-value of p ≤ 0.05 (*). C.)
IFNγ Difference in production level in PBS and MASP is statistically significant with a P-value of
**= p ≤ 0.01. D.) IL-12 Difference in production level in PBS and MASPsyn is statistically significant
with a P-value of p ≤ 0.05 (*). E.) IL-17, Difference in production level in PBS and MASPsyn is
statistically significant with a P-value of p ≤ 0.05 (*). Each bar represents the mean (n=4/group) for
the different groups.
3.10 Detection of CD4+ and CD8+ in immunized mice using Flow Cytometry
In order to evaluate the role of the vaccine in the cellular immune response, we analyzed the
activation of CD4+ and/or CD8+ T-cells. T-cells were isolated from spleens of non-infected and
acutely infected mice of all groups after 8 days of infection. Activation was determined by using two
different known activation markers, CD25 and CD69 [74]. Mice immunized with AlOH at the acute
level of infection, had an overwhelming CD4+ and CD8+ T cell activation (Figure 9). Clearly AlOH is
not able to stimulate the adequate immune response in fact it seems to over stimulate the response
possibly leading to early death in infected mice. When looking at mice immunized with either
MASPsyn or MASPsyn /AlOH, in both infected and non-infected mice, the activation of CD4+ and
CD8+ seems to have a homeostatic effect, when monitored with either marker.

Upon infection

immunized mice are also able to provide a higher activation when compared to the placebo group.
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Figure 3.12. CD4+ and CD8+ activation in acute phase and non-infected mice. Cells were stained for
A.) CD4+ and CD25 markers. B.) CD4+ and CD69 marker. C.) CD8+ and CD25 markers. D.) CD8+
and CD69 markers.

Samples were done in triplicates and analyzed using flow cytometry.

Immunized mice show to have a better regulatory system of activation when compared to the two
control groups (PBS and AlOH).
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3.11 Detection of CD4+ and CD8+ in mice with chronic stage infection using Flow Cytometry
The immunized mice that were challenged with 1x104 trypomastigotes develop a chronic
disease and some of them survive until nine months when the experiment was terminated. In order to
analyze the production of MASPsyn-specific CD4+ and C8+ T cell a boost immunization was
administered seven days before euthanize the mice. The spleen was collected just after the animals
were sacrificed and the specific T cell production measured using as CD25 and CD69 as markers for
CD4+ and C8+ T (Figure 3.12). It is interesting that mice in the AlOH group died early on therefore,
we did not have a chronic model for this group. We were able to compare the non-infected AlOH
immunized to all the other groups, since the animals were kept alive.

Mice that were immunized

with MASPsyn and not infected are usually used for collection of serum for other experiments, so there
weren’t animals available that were immunized, not infected at this age. The overall T lymphocyte
level was low as expected in mice at this age. Interestingly, it was an overall slight activation of
CD4+/CD8+ T cells in the mice challenged immunized with MASPsyn or MASPsyn/AlOH (Figure 3.12),
so we can assume that the vaccine was able to stimulate the population of T. cells that had “memory”.
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Figure 3.13. CD4+ and CD8+ activation in chronic phase and non-infected mice. Cells were stained
for A.) CD4+ and CD25 markers. B.) CD4+ and CD69 marker. C.) CD8+ and CD25 markers. D.)
CD8+ and CD69 markers.
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3.12 In vivo depletion of immune cell subsets
Parasitemia and survival of mice infected, immunized with PBS, KLH or MASPsyn), and
depleted of CD4+ or CD8+ were followed to show the role of T cells in the protection by the vaccine.
Mice in KLH and PBS groups that were depleted with either T cell type showed higher mortality, and
uncontrollable parasitemia. Mice immunized with MASPsyn and treated with α-CD8 did not show
difference in survivability, but rather a prolonged life. Parasitemia in this group seemed to be
controlled until day 15, with a late peak of parasites (17th day) and no detected parasitemia at day 19.
Mice immunized with MASPsyn and treated with α-CD4 showed increase survival and lower
parasitemia, when compared to the other groups.

Figure 3.14. Survival and parasitemia of mice depleted of CD4+ or CD8+ T cells. A.) Survival of
mice treated with α-CD4. B.) Parasitemia of mice treated with α-CD4. C.) Survival of mice treated
with α-CD8. D.) Parasitemia of mice treated with α-CD8. Immunized mice with vaccine seem to
have better response to infection of T. cruzi.
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Chapter 4: Discussion
The original goal of this study was to evaluate MASPves protein as a candidate against Chagas
disease. After an unsuccessful attempt to produce a recombinant MASPves vaccine, our alternate
approach was to synthetically develop a peptide.

Furthermore, we evaluated the efficacy of a

synthetic peptide (MASPsyn) based vaccine. As previously discussed the optimal vaccine for Chagas
disease is that is able to stimulate both a humoral and cell mediated immune response. We therefore
assed the parasitemia, survivability, and the humoral and cell mediated immune response to evaluate
the success of the vaccine. Although there was no sterile protection against the infection, there were
several relevant results that showed that our vaccine is a good candidate and it could be optimized for
the development of a prophylactic vaccine.
The humoral response plays a key role in controlling parasitic infection [61, 75]. Antibodies
have shown to have importance in both the chronic and acute stage of the disease. Serum transferred
from chronically infected mice to naïve mice showed reduced parasitemia and prolonged survival
after challenge [76, 77]. In addition, in the acute phase of the disease B cells also play a valuable role
in recruiting CD4+ and CD8+ T cells and maintaining memory and effector T cells [78]. We evaluated
the humoral response by antibody production of immunized mice, here we analyzed the antibody Ig
isotyping stimulation and evaluated lytic activity of α-MASPsyn. The levels of antibody production
against the synthetic peptide were first evaluated in serum from human Chagasic patients as a positive
control, since ideally this vaccine would be for human use. This study suggests that MASPsyn induce
immunity stimulation in a natural infection. As expected, immunized mice with MASPsyn produced
antibodies against the peptide as well as MASPsyn/AlOH. Increasing levels of antibody production in
MASPsyn/AlOH can be explained by the ability of AlOH to aid production of antibodies through CD4+
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T cells [48]. We speculate that early death in mice immunized with AlOH was a result of an over
inflammation response from both this adjuvant and the parasite challenge.
Recently it was suggested that the MASP family and other surface molecules may contribute
to hypergammaglobulinemia seen in the acute stages of the disease [79]. Our further examination of
the Ig isotype of the antibodies reveled appealing results. Our data established that immunized mice
have a higher amount of IgG1, IgG2A, IgA, and IgM. We found that IgA, IgM and IgG showed
significant high titers in the MASPsyn immunized animals, which after challenge have 80 % survival.
These results are supported by the literature described the anti-parasitic effects of these Igs in the
murine model of Chagas disease [62-64]. Interestingly, when antigens from different life stages of the
parasite were tested for immunogenicity in serum from infected individuals, increase levels of IgA,
IgM and IgG levels are detected [80]. Also, IgG1 and IgG2 have been shown to attribute to the
elimination of the parasite and decrease of mortality [81-83]. In addition, IgG1 and IgG3 have been
demonstrated to help in the clearance of other parasites such as Schistosoma mansoni and
Plasmodium falciparum [84-86].
In the acute phase of the disease antibodies are produced against surface molecules of the
trypomastigote form [87]. The protective antibodies have the capacity to agglutinate trypomastigotes,
lyse them in a complement-mediated path, help in phagocytosis/opsonization, and mediate antibodydependent cellular cytotoxicity [88-92]. We showed that MASPsyn produce lytic antibodies that help
in the direct killing of trypomastigotes.
Regarding the T-cell specific immune response, the cytokine profile (IL-4, IL-10, IL-12, IL17A, and IFN-γ) relevant in the control infection was analyzed. Cytokine IL-4 was shown to be
stimulated at higher levels in MASPsyn and in MASPsyn/AlOH serum. This is interesting since it has
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been published that IL-4 is a stimulating factor for the differentiation and proliferation of B cells [93],
supporting the higher antibody production as well in these two groups.
IL-4 is not a major determinant of susceptibility to a T. cruzi infection, but IL-4 and IL-10 in
association have been demonstrated to control myocarditis [66]. It has also been shown that if IL-4 is
more dominant than IL-10 parasitemia is enhanced [67]. This is interesting since our vaccine is able
to stimulate more dominance IL-10 than IL-4.

IL-10 during infection can actually increase

parasitemia, however, it is essential for survival. Mice that are depleted of IL-10 show lower
parasitemia, but higher mortality [70]. IL-10 is able to prevent inflammatory damage and thus
mortality as well [68, 69]. In our case the MASPsyn is increased, but still had less production than
MASPsyn/AlOH, showing some homeostasis. IL-12 is also important for controlling infection, IL-12
KO mice showed higher parasitemia and mortality [67, 94]. IL-12 and IFN- γ are crucial to lower
parasitemia, mortality and lower inflammation, respectively [70, 71]. IFN-γ has been identified as a
resistant player in the infection of T. cruzi [95]. Also, the addition of recombinant IFN-γ to mice
increases resistance of T. cruzi and neutralizing it causes susceptibility [95]. In our case, both IL-12
and IFN- γ are produced at high levels when compare to the control. IL-17A levels of our immunized
mice showed statistically significant increase levels when compared to the placebo immunized mice.
This is relevant since IL-17 helps regulate extracellular and intracellular pathogens [96]. Moreover,
IL-17 has been shown to play a role in regulating parasite-induced myocarditis and aid in parasitemia
and survivability [97, 98]. More specifically IL-17A was recently demonstrated to play a vital role in
resistance of a T. cruzi infection [73]. Additionally, IL-17 was shown to be produced during acute
phase of infection, is able to control cardiac inflammation by modulating a Th1 response [97]. After
closely analyzing and associating cytokine production we speculate that this vaccine is activating a
Th1, Th9, and Th17 response. Th1 response, through production of IFN-γ, has been linked to T.

44

cruzi [99]. Also, Th1 response that produces IL-12 and IFN-γ are important for protection against a
variety of intracellular pathogens [100]. Furthermore, IFN-γ is the main cytokine that stimulates
isotype switching to the IgG1 and IgG3 subclasses eliciting a Th1 response [101]. Therefore, our
results seem to corroborate all this cascade of events supporting activation of Th 1 results. Th9 in T.
cruzi infection has not been explored, but it is known to play roles in pro-inflammatory and function
in many autoimmune diseases and allergic inflammation [102]. Also, Th9 cells secrete high amounts
of IL-10 and to differentiate in the presence of TGF-β and IL-4 [102]. As mentioned briefly above
IL-10 and IL-4 both play essential roles in infection. Th9 has also been shown to contribute to the
differentiation of Th17 by the secretion of IL-9 [102]. Lastly, Th17 cells, through the production of
IL-17 family, are known to be critical for the clearance of extracellular pathogens [103]. Hence, Th1,
Th9 and Th17 responses all seem to reflect the cytokine profile that we see with the vaccine.

Figure 4.1. Model of the T and B cell activation by MASPsyn in immunized mice
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Cellular immune response was also analyzed by determining the percentage of activation of
CD4+ and CD8+ T cells in both non-infected, immunized mice and in acute and chronic phase
immunized mice. Chronic infected mice showed a slight activation of both T lymphocytes upon
boost, which shows that memory was created. In the acute stage of infection mice immunized (noninfected or infected), had a greater activation response from both cells. The activations seem to
reflect a homeostatic effect between the cells, probably contributing to the increase survivability and
controlling of the disease. Mice with the chronic stage of the disease, although showing the expected
overall low lymphocyte number because of their age [104-107], also showed a slight increase in
activation within immunized-infected mice. Furthermore, we also abolished either CD4+ or CD8+ in
immunized mice and then challenged. We concluded that the vaccine is probably protecting through
more on stimulation of CD8+ T cells, since mice with the depletion of CD8+ died and had greater
parasitemia, developing at a later time. This was also confirmed by the mice with depleted CD4+ in
which the animals were able to prolong death or survive and had lower parasitemia.

This is

encouraging since CD8+ T lymphocytes have been established to be important of protective immunity
against this parasite [108, 109].
It is important to highlight that one year after the challenge (with 1 x 106 parasites) the mice
immunized with MASPsyn alone showed 80% survival, more than any other infected mouse in the
experimental groups. Early in the infection MASPsyn mice showed high parasitemia, however from the
8th – 18th day post infection lower parasitemia was maintained, and no parasites were detected in
blood after. Most noticeable the vaccine was able to significantly reduce the level of parasites in
heart, liver, spleen, probably attributing to the survival of the mice.
In conclusion, surface proteins, such as MASPs, are intriguing epitopes to study for
vaccination purposes because of their visibility to host cells. In this study we have provided evidence
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of a synthetic based vaccine based, MASPsyn, is able to effectively control T. cruzi infection,
prolonging survival, and possible reducing progression of the disease. This might be able to be an
alternate treatment to the present drug therapy used to treat Chagas disease. The vaccine has shown
to also elicit an ideal immune stimulation, therefore, we foresee that efforts in the optimization of this
vaccine candidate, through improving delivery system (e.g. virus particles approach), immunizations
protocols, adjuvant and carrier molecules, will provide a full protective vaccine against Chagas
disease.
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